Related Experiment Video
Updated: Apr 1, 2026
Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line
Published on: February 8, 2022
Potential Application of CAR-NK Cells as an Ex Vivo Therapy for T-cell-related Diseases
Daekee Kwon1,2, Kyung-Sun Kang3
1Research Institute, Maru Therapeutics Co., Ltd., Seoul BioHub Global Center, Dongdaemun-gu, 02455 Seoul, Republic of Korea.
Abstract:
Anticancer therapeutics have evolved from small-molecule drugs to monoclonal antibodies and, more recently, to cell and gene therapies (CGTs). This progress has been driven by the pursuit of greater drug specificity, potency, and safety. Recent breakthroughs in chimeric antigen receptor T-cell (CAR-T) therapy for B-cell hematologic malignancies have accelerated the development of CAR-X CGTs, including CAR-T, CAR-natural killer (CAR-NK), and CAR-macrophage approaches. In this article, we compare candidate CAR-X platforms for T-cell-related diseases, such as T-cell hematologic malignancies, and propose the most suitable modality. Therefore, we analyzed the advantages and limitations of CAR-T, CAR-NK, and CAR-macrophage therapies. In T-cell-related diseases, CAR-T therapy faces multiple challenges, including fratricide, T-cell aplasia, and substantial barriers to the generation of allogeneic CAR-T products. CAR-macrophage therapies, in contrast, are constrained by relatively limited efficacy. In contrast, CAR-NK cells do not cause fratricide or T-cell aplasia and can be manufactured efficiently as allogeneic, "off-the-shelf" products. Collectively, to sustain and extend the advances in CGT initiated by CAR-T cells in B-cell malignancies, prioritizing CAR-NK research infrastructure for T-cell-related diseases represents a rational and strategic approach.
Insights
Chimeric antigen receptor (CAR)-NK cells are a promising cell and gene therapy (CGT) for T-cell malignancies. Unlike CAR-T therapies, CAR-NK cells avoid fratricide and offer efficient, off-the-shelf allogeneic manufacturing.
Area of Science:
- Oncology
- Immunotherapy
- Cell and Gene Therapy
Background:
- Anticancer therapeutics have advanced from small molecules to cell and gene therapies (CGTs).
- Chimeric antigen receptor T-cell (CAR-T) therapy has shown success in B-cell malignancies, spurring development of other CAR-X CGTs.
- CAR-X platforms include CAR-T, CAR-natural killer (CAR-NK), and CAR-macrophage therapies.
Purpose of the Study:
- To compare CAR-X platforms for T-cell-related diseases.
- To identify the most suitable CAR-X modality for T-cell malignancies.
- To analyze the advantages and limitations of CAR-T, CAR-NK, and CAR-macrophage therapies.
Main Methods:
- Comparative analysis of CAR-T, CAR-NK, and CAR-macrophage platforms.
- Evaluation of therapeutic efficacy, safety, and manufacturing considerations.
- Assessment of challenges specific to T-cell malignancies.
Main Results:
- CAR-T therapy faces challenges in T-cell diseases, including fratricide, T-cell aplasia, and allogeneic manufacturing barriers.
- CAR-macrophage therapy shows limited efficacy for T-cell malignancies.
- CAR-NK cells do not cause fratricide or T-cell aplasia and can be efficiently manufactured as allogeneic, off-the-shelf products.
Conclusions:
- CAR-NK cells present a viable alternative to CAR-T therapy for T-cell malignancies.
- Prioritizing CAR-NK research infrastructure is a strategic approach to advance CGT for T-cell diseases.
- CAR-NK therapy offers a promising, off-the-shelf solution with improved safety and manufacturing profiles.
More Related Videos
Related Concept Videos
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:27Tumor Immunotherapy